Dual-Chelator conjugates for [68Ga]Ga- and [177Lu]Lu-based PSMA Radiotheranostics
Bioorganic Chemistry · 2026-09 · 180 · 110236
DOI: 10.1016/j.bioorg.2026.110236 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026-09. Verfasst von Wenbin Jin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 10…. Hauptthemen laut MEDLINE: Gallium Radioisotopes, Lutetium, Chelating Agents, Radiopharmaceuticals. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National High-tech Research and Development Program, National Natural Science Foundation of China.
Abstract (Originalsprache)
Prostate-specific membrane antigen (PSMA) is highly overexpressed in prostate cancer (PCa) and represents an attractive target for radiotheranostic applications. While conventional approaches often convert PSMA-targeted imaging agents into therapeutic counterparts through chelator substitution, we explored a dual-chelator strategy by integrating HBED-CC and DOTA into the PSMA-093 scaffold. This design generated three dual-chelator conjugates (1-3) capable of supporting the chelation of both diagnostic and therapeutic radionuclides within a single molecular platform. The compounds were successfully radiolabeled with [68Ga]Ga3+ and [177Lu]Lu3+, and mass spectrometric analysis confirmed site-selective coordination of Ga3+ by HBED-CC and Lu3+ by DOTA. All conjugates retained high PSMA-binding affinity in vitro, with [68Ga]Ga/[177Lu]Lu-2 and [68Ga]Ga/[177Lu]Lu-3 demonstrating enhanced cellular uptake in 22Rv1-FOLH-oe (PSMA overexpression) cells. In vivo PET/CT imaging and biodistribution studies revealed that [68Ga]Ga-2 exhibited favorable pharmacokinetics, including rapid background clearance and improved tumor retention. Importantly, [177Lu]Lu-2 achieved high tumor uptake, reaching 8.35%ID/g at 24 h post-injection, indicating effective tumor targeting and prolonged retention. These findings support the dual-chelator strategy as a promising platform for the development of next-generation PSMA-targeted radiotheranostic agents. By enabling efficient integration of diagnostic imaging and radionuclide therapy within a single molecule, this approach offers enhanced flexibility for radiopharmaceutical design while preserving favorable biological performance. The dual-chelator concept may facilitate the development of more effective companion diagnostic-therapeutic pairs and contribute to the advancement of precision oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100875, China.
- Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, China.
- Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, United States. Electronic address: kunghf@gmail.com.
Förderung
- National High-tech Research and Development Program
- National Natural Science Foundation of China
Zitieren
APA
Jin, W., Luo, Y., Zhu, Z., Zhu, L., & Kung, H. F. (2026). Dual-Chelator conjugates for [68Ga]Ga- and [177Lu]Lu-based PSMA Radiotheranostics. Bioorganic Chemistry, 180, 110236. https://doi.org/10.1016/j.bioorg.2026.110236
Vancouver
Jin W, Luo Y, Zhu Z, Zhu L, Kung HF. Dual-Chelator conjugates for [68Ga]Ga- and [177Lu]Lu-based PSMA Radiotheranostics. Bioorganic Chemistry. 2026;180:110236. doi:10.1016/j.bioorg.2026.110236
BibTeX
@article{Jin2026,
author = {Jin, Wenbin and Luo, Yang and Zhu, Zhaohui and Zhu, Lin and Kung, Hank F},
title = {Dual-Chelator conjugates for [68Ga]Ga- and [177Lu]Lu-based PSMA Radiotheranostics},
journal = {Bioorganic Chemistry},
year = {2026},
volume = {180},
pages = {110236},
doi = {10.1016/j.bioorg.2026.110236}
}
EUVIMED